| pubmed-article:2966029 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2966029 | lifeskim:mentions | umls-concept:C0018802 | lld:lifeskim |
| pubmed-article:2966029 | lifeskim:mentions | umls-concept:C0027481 | lld:lifeskim |
| pubmed-article:2966029 | lifeskim:mentions | umls-concept:C0520010 | lld:lifeskim |
| pubmed-article:2966029 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2966029 | pubmed:dateCreated | 1988-6-8 | lld:pubmed |
| pubmed-article:2966029 | pubmed:abstractText | Atrial natriuretic peptide (ANP) induces potent diuretic/natriuretic, vasorelaxing and aldosterone inhibitory effects. Increased plasma levels in congestive heart failure (CHF) have been reported. The aim of this study was to investigate plasma immunoreactive ANP (ir-ANP) levels during acute treatment of CHF. Seven patients with CHF underwent cardiac catheterization. Ir-ANP plasma levels were followed up to two h after administration of an orally given phosphodiesterase inhibitor (Milrinone); a substance with positive inotropic and peripheral vasodilating properties. In all patients cardiac output increased and cardiac filling pressures decreased markedly. Initially high ir-ANP plasma levels decreased. Our patients did not have an increased blood volume. It is concluded that plasma ir-ANP levels in the pulmonary artery rapidly decrease when atrial pressure is reduced. These data suggest that atrial pressure is the major determinant for release of ir-ANP in man and that the ability to respond quickly to changes in cardiac filling pressures is maintained in patients with severe CHF. Plasma ir-ANP levels may also become useful as an index of the degree of heart failure and serve as a tool in monitoring response to drug therapy. | lld:pubmed |
| pubmed-article:2966029 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2966029 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2966029 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2966029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2966029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2966029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2966029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2966029 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2966029 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:2966029 | pubmed:issn | 0144-5979 | lld:pubmed |
| pubmed-article:2966029 | pubmed:author | pubmed-author:HednerTT | lld:pubmed |
| pubmed-article:2966029 | pubmed:author | pubmed-author:BevegårdSS | lld:pubmed |
| pubmed-article:2966029 | pubmed:author | pubmed-author:CarlensPP | lld:pubmed |
| pubmed-article:2966029 | pubmed:author | pubmed-author:HednerJJ | lld:pubmed |
| pubmed-article:2966029 | pubmed:author | pubmed-author:BerglundHH | lld:pubmed |
| pubmed-article:2966029 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2966029 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:2966029 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2966029 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2966029 | pubmed:pagination | 155-62 | lld:pubmed |
| pubmed-article:2966029 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2966029 | pubmed:meshHeading | pubmed-meshheading:2966029-... | lld:pubmed |
| pubmed-article:2966029 | pubmed:meshHeading | pubmed-meshheading:2966029-... | lld:pubmed |
| pubmed-article:2966029 | pubmed:meshHeading | pubmed-meshheading:2966029-... | lld:pubmed |
| pubmed-article:2966029 | pubmed:meshHeading | pubmed-meshheading:2966029-... | lld:pubmed |
| pubmed-article:2966029 | pubmed:meshHeading | pubmed-meshheading:2966029-... | lld:pubmed |
| pubmed-article:2966029 | pubmed:meshHeading | pubmed-meshheading:2966029-... | lld:pubmed |
| pubmed-article:2966029 | pubmed:meshHeading | pubmed-meshheading:2966029-... | lld:pubmed |
| pubmed-article:2966029 | pubmed:meshHeading | pubmed-meshheading:2966029-... | lld:pubmed |
| pubmed-article:2966029 | pubmed:meshHeading | pubmed-meshheading:2966029-... | lld:pubmed |
| pubmed-article:2966029 | pubmed:meshHeading | pubmed-meshheading:2966029-... | lld:pubmed |
| pubmed-article:2966029 | pubmed:meshHeading | pubmed-meshheading:2966029-... | lld:pubmed |
| pubmed-article:2966029 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2966029 | pubmed:articleTitle | Atrial natriuretic peptide during acute treatment of congestive heart failure. | lld:pubmed |
| pubmed-article:2966029 | pubmed:affiliation | Department of Clinical Physiology, Karolinska Institute, Södersjukhuset, Stockholm, Sweden. | lld:pubmed |
| pubmed-article:2966029 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2966029 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
